semaglutide
Semaglutide and Mental Health: A Complex Relationship
semaglutide, mental health, suicidal ideation, GLP-1 drugs, weight loss, diabetes
Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges
Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market
Novo Nordisk Pursues FDA Filing for Once-Weekly Insulin and Semaglutide Combo After Icodec Rejection
Novo Nordisk, insulin icodec, semaglutide, FDA filing, type 2 diabetes, once-weekly insulin, IcoSema, COMBINE-1 study, regulatory approval
Novo Nordisk’s Once-Weekly Insulin Icodec Faces FDA Rejection and Manufacturing Concerns
Novo Nordisk, icodec, FDA rejection, once-weekly insulin, manufacturing issues, type 1 diabetes, type 2 diabetes, semaglutide, IcoSema
Novo Nordisk Expands Legal Campaign Against Compounders of GLP-1 Drugs
Novo Nordisk, GLP-1 drugs, compounded drugs, legal campaign, patient safety, semaglutide
Lilly’s Tirzepatide Clears Phase III Cardiovascular Study on Heels of Novo Nordisk’s Semaglutide
Tirzepatide, Lilly, Phase III, Cardiovascular Study, Novo Nordisk, Semaglutide, Heart Failure, Obesity, Weight Loss
Novo Nordisk’s Wegovy Receives UK Approval to Reduce Cardiovascular Risks in Overweight and Obese Adults
Wegovy, Novo Nordisk, UK approval, cardiovascular risks, weight loss, obesity, GLP-1 receptor agonist, semaglutide
Layoffs Persist, GLP-1s Launch for Weight Loss in China
GLP-1, weight loss, China, Novo Nordisk, Eli Lilly, layoffs, biopharma industry, semaglutide, tirzepatide, obesity, diabetes
Eli Lilly’s Tirzepatide Approved in China for Weight Loss Management Amid Growing Obesity Concerns
Eli Lilly, Tirzepatide, Weight Loss, China, Obesity, Novo Nordisk, GLP-1 Agonists, Diabetes, Mounjaro, Zepbound, Semaglutide, Wegovy
Novo Nordisk Wins Approval in China for GLP-1 Obesity Drug Wegovy
Novo Nordisk, Wegovy, GLP-1, Obesity, China, Weight Loss, Semaglutide, Ozempic